Key highlights
- 8 out of 9 evaluable patients (89%) achieved a clinically meaningful reduction in SLEDAI-2K scores
- 4 out of 7 patients with high baseline proteinuria achieved a complete renal response within 24 weeks
- No Grade 3 or higher cytokine release syndrome (CRS) or neurotoxicity events were observed
- Clinical activity was supported by reductions in anti-dsDNA antibodies and depletion of CD19-positive B cells
- Management confirms a cash runway into 2029 with $356 million in total liquidity as of August 2026
Clinical Trial Performance
On November 8, 2026, Cullinan Therapeutics announced interim clinical data from an ongoing Phase 1b/2a trial evaluating velinotamig, a BCMAxCD3 T cell engager, in patients with refractory systemic lupus erythematosus (SLE). Presented at the ACR Convergence 2026, the data showed that eight of nine evaluable patients achieved a reduction of at least four points in the SLEDAI-2K disease activity index. Furthermore, four out of seven patients with elevated baseline proteinuria reached a complete renal response within 24 weeks. The therapy demonstrated a favorable safety profile with no observed Grade 3 or higher cytokine release syndrome or neurotoxicity events across three multi-dose cohorts.
Strategic Development and Licensing
The interim results validate velinotamig mechanism as a short-duration B-cell maturation antigen-directed therapy. By depleting pathogenic autoantibody-producing plasma cells, the drug aims to address the underlying drivers of severe autoimmune conditions. Cullinan holds an exclusive global license, excluding Greater China, for velinotamig from Chongqing Genrix Biopharmaceutical. These data support the company broader strategy to expand into autoimmune cytopenias, where an IND clearance was recently obtained to initiate global Phase 1b/2a trials. The absence of dose-limiting toxicities in this cohort provides a competitive safety baseline compared to other cell therapy platforms currently in development for autoimmune indications.
Management Perspective
“These compelling early findings demonstrate consistent and meaningful clinical, serological, and pharmacodynamic evidence in most treated patients, further validating the therapeutic potential of velinotamig as a short-duration BCMA-directed therapy.”
Financial and Pipeline Context
- Cullinan reports $356 million in cash and investments, projected to fund operations into 2029
- A PDUFA target action date of February 27, 2027, is set for zipalertinib in NSCLC
- The company recently dosed the first patient in a registrational Phase 2 trial for CLN-049 in AML
- Pipeline expansion includes planned trials for autoimmune cytopenias following recent regulatory clearances
- Velinotamig development continues in China via partner Genrix Bio with multi-dose escalation cohorts
Down 16.0% since our story on 9 Nov: $11.31 when we broke it → $9.50 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $13.98 |
|---|---|
| 20 Oct | $14.83 |
| 21 Oct | $14.89 |
| 22 Oct | $14.92 |
| 23 Oct | $14.37 |
| 26 Oct | $14.54 |
| 27 Oct | $14.84 |
| 28 Oct | $15.56 |
| 29 Oct | $15.45 |
| 30 Oct | $15.03 |
| 2 Nov | $14.93 |
| 3 Nov | $15.75 |
| 4 Nov | $12.49 |
| 5 Nov | $10.80 |
| 6 Nov | $11.31 |
| 9 Nov | $11.73 |
| 10 Nov | $11.23 |
| 11 Nov | $11.35 |
| 12 Nov | $10.19 |
| 13 Nov | $10.28 |
| 16 Nov | $9.50 |
Industry Landscape
The treatment of systemic lupus erythematosus is shifting toward precision depletion of B-cell populations to achieve long-term remission in refractory patients. Standard of care frequently fails to provide adequate control for moderate-to-severe cases, particularly those involving renal complications. T cell engagers like velinotamig represent an emerging class of off-the-shelf biologics that offer potential advantages over personalized cell therapies, including simplified administration and more predictable safety profiles. The biotechnology sector is currently seeing significant capital redirected toward autoimmune applications of platforms originally proven in hematologic oncology.
| Date | Announcement | Amount |
|---|---|---|
| 08 Nov 2026 | Presentation of Phase 1b/2a clinical data for velinotamig demonstrating complete renal responses in systemic lupus erythematosus at ACR Convergence 2026Source: ca.investing.com | – |
| 04 Nov 2026 | Announcement of upcoming clinical presentations for CLN-049 and velinotamig at the 68th ASH Annual MeetingSource: SEC filing | – |
| 27 Oct 2026 | FDA and Australian TGA clearance of IND to initiate global Phase 1b/2a trial of velinotamig in autoimmune cytopeniasSource: investors.cullinantherapeutics.com | – |
| 19 Oct 2026 | Presentation of Phase 2 REZILIENT2 trial data demonstrating intracranial antitumor activity of zipalertinib in NSCLC with CNS metastasesSource: investors.cullinantherapeutics.com | – |
| 08 Oct 2026 | First patient dosed in planned registrational Phase 2 trial of CLN-049 in relapsed/refractory acute myeloid leukemiaSource: investors.cullinantherapeutics.com | – |
| 01 Oct 2026 | Initiation of New Drug Application (NDA) submission for zipalertinib plus chemotherapy under FDA Real-Time Oncology Review programSource: investors.cullinantherapeutics.com | – |
Management commentary
“Combined with the favorable safety profile observed to date, these data reinforce our confidence in the global development plan for velinotamig, including our initial focus on autoimmune cytopenias, where pathogenic autoantibody-producing plasma cells play a central role in disease pathogenesis.”
| Share price | $11.31 |
|---|---|
| Market cap | $728M |
| 1-month price change | -27.64% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Cullinan Therapeutics, Inc. announcing interim Phase 1b/2a clinical data for velinotamig in systemic lupus erythematosus.
Track Cullinan Therapeutics, Inc. live
Get the next Cullinan Therapeutics, Inc. SEC filing seconds after it lands.